[1] Ganem D,Prince AM. Hepatitis B virus infection-natural history and clinical conesquences. N Engl J Med,2004,350（11）:1118-1129.
[2] World Health Organization,Hepatitis B（[EB/OL]）. （Revised August 2008）. [2010-12-9]. Http:www.who.int/mediacentre/factsheets/fs204/en/.
[3] Bosch FX,Ribes J,Cleries R,et al. Epidemiology of hepatocellular carcinoma. Clin Liver Dis,2005,9（2）:191-211.
[4] Chen CJ,Yang HI,Su J,et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA,2006,29（5）:65-73.
[5] Lok AS,Mcmahon BJ. Chronic hepatitis B:update 2009. Hepatology,2009,50（3）:661-662.
[6] Lok AS,Lai CL,Leung N,et al. Long-term safety of lamivudine treatm-ent in patients with chronic hepatitis B. Gastroenterology,2003,125 （6）:1714-1722.
[7] 贾克东,万里晖,刘南田,等. 拉米夫定治疗慢性乙型肝炎108 例疗效分析. 实用肝脏病杂志,2008,11（16）：408-409.
[8] Marcellin P,Chang TT,Lim SG,et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology,2008,48（3）:750-758.
[9] Gish RG,Lok AS,Chang TT,et al. Entecavir therapy for up to 96 weeks in patients with HBeAg positive chronic hepatitis B.Gastroenterology,2007,13（3）:1437-1444.
[10] Lai CL,Lim SG,Brown NA,et al. A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology,2004,40（3）:719-726.
[11] Sung JJ,Lai JY,Zeuzem S,et al. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. Hepatology,2008,48（5）:728-735.
[12] Wang LC,Chen EQ,Cao J,et al. De novo combination of lamivudine and adefovir versus entecavirmonotherapy for the treatment of naive HBeAg-negative chronic hepatitis B patients. Hepatol Int,2011,5（2）:671-676.
[13] Hadziyannis SJ,Papatheodoridis GV. Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection. Expert Rev Anti Infect Ther,2004,2（4）:475-483.
[14] 霍丽亚.拉米夫定联合阿德福韦酯治疗失代偿期乙型肝炎肝硬化的临床观察. 实用肝脏病杂志,2008,11（6）:378.
[15] Liaw YF. Hepatitis B virus replication and liver disease progression:the impact of an tiviral therapy. Antivir Ther,2006,11（16）:669-679.
[16] Lai CL,Leung N,Teo EK,et al. A 1-year trial of telbivudine, lamivudine,and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology,2005,129 （2）:528-536.
[17] Ha NB,Garcia RT,Trinh HN,et al. Medication nonadherence with long-term management of patients with hepatitis B e antigen-negative chronic hepatitis B. Dig Dis Sci,2011,56（8）:2423-2431.
[18] Dai CY,Chuang WL,Hsieh MY,et al. Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B. Antiviral Ras,2007,75（5）:146-151.
[19] 邵幼林,张锁才,陈良云,等. LAM耐药后ADV序贯治疗再耐药HBV变异株的动态变化.世界华人消化杂志,2010,18（18）：1895-1901.
[20] 郑建铭,张永信. 抗乙型肝炎病毒药物的合理应用. 上海医药,2010,31（9）：389-393.
[21] Rapti I,Dimou E,Mitsoula P,et al. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology,2007,45（2）:307-313.
[22] Yatsuji H,Suzuki F,Sezaki H,et al. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy:two year follow-up. Hepatology,2008,48（6）:923-931.
[23] Perrillo RP,Hann hw,Schiff E,et al.Extended treatment with lamivudine and adefovir dipivoxil inchronic hepatitis B patients with lamivudine resistance. Hepatology,2011,5（2）:654-663.
[24] Ash SH,Kweon YO,Paik SW,et al. Telbivudine in combination with adefovir versus adefovir monotherapy in HBeAg-positive,lamivudine-resistant chronic hepatitis B. Hepatol Int. 2011 Oct 12[Epub ahead of print].
[25] Zaaijer HL,Takkenberg RB,Weegink CJ,et al. Susceptibility of hepatitis B virus to lamivudine restored by resistance to adefovir. J Med Virol,2009,81（3）:413-416.
[26] Manolakopoulos S,Bethanis S,Koutsounas S,et al. Long-term therapy with adefovir dipvoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine. Aliment Pharmacol Ther,2008,27 （3）:266-273.
[27] Park JW,Kim HS,Seo DD,et al. Long-term efficacy of entecavir in adefovir-refractory chronic hepatitis B patients with prior lamivud-ine resistance. J Viral Hepat,2011,18（10）:475-481.
[28] Hadziyannis SJ,Tassopoulos NC,Henthcote EJ,et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology,2006,131（6）:1743-1751.
[29] Locarnini S,Mason WS. Cellular and virological mechanisms of HBV drug resistance. J Hepatol,2006,44（2）:422-431.
[30] Wong CR,Trinh HN,Yip B,et al. High rate of complete viral suppression with combination therapy in patients with chronic hepatitis B and prior treatment failure. J Clin Gastroenterol,2011,45（10）:900-905. |
